Response to Comments: MolDX: Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This excerpt is an administrative notice (response to comments) for MolDX LCD DL38047 concerning next-generation sequencing lab-developed tests for myeloid malignancies; it provides comment, notice, and effective dates but does not contain clinical coverage criteria. Consult the full LCD DL38047 (MolDX: Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies) for specific indications, limitations, documentation requirements, and frequency limits.